AbCellera is a Canadian biotechnology company headquartered in Vancouver, built around a proprietary antibody discovery platform that it licenses to pharmaceutical and biotech partners developing new drug candidates. Listed on Nasdaq under the ticker ABCL.O, the company gained widespread recognition during the COVID-19 pandemic as the discoverer of bamlanivimab, an antibody treatment developed in partnership with Eli Lilly and Company, which brought both revenue and visibility to a business that had previously operated largely below mainstream investor radar.
The underlying business model is distinctive: rather than advancing drugs through the full clinical pipeline itself, AbCellera acts as an upstream discovery partner, taking royalties and milestones as its partners progress candidates towards commercialisation. That royalty-driven structure gives the company long-term revenue potential largely decoupled from the operational complexity of running clinical trials, though near-term income can be lumpy and heavily dependent on partner development timelines.
Please note this is marketing communication, not recommendation or advice.
klientkontoer
FxPro har levert elektroniske handelstjenester til kundene sine siden 1999 og er for tiden aktiv i 173 land verden over.
Priser
FxPro har kontinuerlig blitt anerkjent i bransjen og har pr. i dag vunnet over 145 internasjonale priser for kvaliteten på tjenestene som tilbys.
kundeservice
Vårt dedikerte og flerspråklige kundeserviceteam jobber hele døgnet for å kunne gi det et eksepsjonelt brukerstøttenivå.
bransjeforskrifter
FxPro opererer under streng regulatorisk overvåkning i flere jurisdiksjoner, inkludert autorisasjon fra FCA i Storbritannia - en av de mest pålitelige finansmyndighetene i verden.
